Alumis Stock

Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.

Sign up today and learn more about Alumis Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Alumis Stock

Alumis is a precision medicines company looking to eliminate the “all-comers” approach that is seen with today’s treatments for people with autoimmune disease. Even with the innovation of the last decade, many patients continue to cycle through the approved therapies while continuing to look for the right therapy to alleviate the impact of their disease without life-impacting side effects. Esker leverages a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease.

Funding History

May 2021$70.0M
January 2022$200M


Board of Directors

Alan Colowick

Board Member

Michael Rome

Chief Development Officer

Mark Bradley

Founder, President & CEO

June Lee

Board Member

Jim Tananbaum

Board Observer

Vikram Bajaj

Head of Research

Ken A Brameld

Vice President, Clinical Operations

Jeff Douglas

Senior Vice President, Chief Information Officer

David Zhang

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: